Updates are available Correction dated 2025-08-15
Click to view Correction: https://doi.org/10.1038/s41434-025-00562-5
-
Authors
Heiss, Christina N.
Riise, Rebecca
Hanse, Eric
Fruhwürth, Stefanie
Zetterberg, Henrik
Björefeldt, Andreas https://orcid.org/0000-0002-1230-3610
-
Funding
Funding for this research was provided by:
Alzheimerfonden (AF-939887, AF-993056)
Hjärnfonden (FO2021-0023)
University of Gothenburg | Sahlgrenska Akademin (GU2020/2376)
Åke Wibergs stiftelse
Vetenskapsrådet (2020-00878)
Vetenskapsrådet (2023-00356, 2022-01018, 2019-02397)
Swedish State Support for Clinical Research
EC | Horizon 2020 Framework Programme (101053962)
Swedish State Support for Clinical Research
- License Information
-
More Information
Article History
Received: 18 July 2024
Revised: 1 April 2025
Accepted: 3 April 2025
First Online: 10 April 2025
Change Date: 22 April 2025
Change Type: Update
Change Details: minor edits were made to author affiliations, main text and figure 1.
Change Date: 13 August 2025
Change Type: Update
Change Details: The original online version of this article was revised: The Competing Interest statement was updated solely on account of the company’s name change.
Change Date: 15 August 2025
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41434-025-00562-5
Competing interests
: An international patent application has been filed based on this work (PCT/EP2024/058078). R.R., E.H., H.Z. and A.B. are shareholders in CERimmune Therapeutics. H.Z. has served on scientific advisory boards and/or as consultant for Abbvie, Acumen, Alector, Alzinova, ALZPath, Amylyx, Annexon, Apellis, Artery Therapeutics, AZTherapies, Cognito Therapeutics, CogRx, Denali, Eisai, Merry Life, Nervgen, Novo Nordisk, Optoceutics, Passage Bio, Pinteon Therapeutics, Prothena, Red Abbey Labs, reMYND, Roche, Samumed, Siemens Healthineers, Triplet Therapeutics, and Wave, has given lectures in symposia sponsored by Alzecure, Biogen, Cellectricon, Fujirebio, Lilly, Novo Nordisk, and Roche, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program (outside submitted work).
